Cancer Biology Program, Program in the Biomedical Sciences, Rackham Graduate School, University of Michigan, Ann Arbor.
Department of Otolaryngology/Head and Neck Surgery, University of Michigan, Ann Arbor.
JAMA Otolaryngol Head Neck Surg. 2013 Dec;139(12):1320-7. doi: 10.1001/jamaoto.2013.5460.
Human papillomaviruses are now recognized as an etiologic factor in a growing subset of head and neck cancers and have critical prognostic importance that affects therapeutic decision making. There is no universally accepted gold standard for high-risk HPV (hrHPV) assessment in formalin-fixed, paraffin-embedded (FFPE) tissue specimens, nor is there a clear understanding of the frequency or role of hrHPV in sites other than oropharynx.
To determine the optimal assessment of hrHPV in FFPE head and neck tumor tissue specimens.
DESIGN, SETTING, PARTICIPANTS: In the setting of a large Midwestern referral center, assessment of hrHPV by p16 immunohistochemical staining, in situ hybridization, and polymerase chain reaction (PCR)-MassArray (PCR-MA), with L1 PGMY-PCR and sequencing to resolve method discordance, was conducted for 338 FFPE oropharyngeal, nasopharyngeal, and oral cavity tumor tissue specimens. Relative sensitivity and specificity were compared to develop a standard optimal test protocol. Tissue specimens were collected from 338 patients with head and neck cancer treated during the period 2001 through 2011 in the departments of Otolaryngology, Radiation Oncology, and Medical Oncology.
Patients received standard therapy.
Optimal hrHPV identification, detection, and activity in head and neck cancers.
Using combined PCR-MA with L1 PGMY-PCR and sequencing for conclusive results, we found PCR-MA to have 99.5% sensitivity and 100% specificity, p16 to have 94.2% sensitivity and 85.5% specificity, and in situ hybridization to have 82.9% sensitivity and 81.0% specificity. Among HPV-positive tumors, HPV16 was most frequently detected, but 10 non-HPV16 types accounted for 6% to 50% of tumors, depending on the site. Overall, 86% of oropharynx, 50% of nasopharynx, and 26% of oral cavity tumors were positive for hrHPV.
PCR-MA has a low DNA (5 ng) requirement effective for testing small tissue samples; high throughput; and rapid identification of HPV types, with high sensitivity and specificity. PCR-MA together with p16INK4a provided accurate assessment of HPV presence, type, and activity and was determined to be the best approach for HPV testing in FFPE head and neck tumor tissue specimens.
人乳头瘤病毒(HPV)现在被认为是越来越多的头颈部癌症的病因,并且具有重要的预后意义,影响治疗决策。在福尔马林固定、石蜡包埋(FFPE)组织标本中,没有被普遍接受的高危 HPV(hrHPV)评估的金标准,也不清楚 hrHPV 在口咽以外部位的频率或作用。
确定在 FFPE 头颈部肿瘤组织标本中评估 hrHPV 的最佳方法。
设计、地点、参与者:在中西部一个大型转诊中心的环境中,对 338 例 FFPE 口咽、鼻咽和口腔肿瘤组织标本进行了 p16 免疫组化染色、原位杂交和聚合酶链反应(PCR)-MassArray(PCR-MA)的 hrHPV 评估,并用 L1 PGMY-PCR 和测序解决方法不一致的问题。该研究共纳入 338 例 2001 年至 2011 年期间在耳鼻喉科、放射肿瘤科和肿瘤内科接受治疗的头颈部癌症患者。
患者接受标准治疗。
对头颈部癌症中 hrHPV 的最佳鉴定、检测和活性。
使用 L1 PGMY-PCR 和测序进行结论性结果的 PCR-MA 检测,我们发现 PCR-MA 的灵敏度为 99.5%,特异性为 100%,p16 的灵敏度为 94.2%,特异性为 85.5%,原位杂交的灵敏度为 82.9%,特异性为 81.0%。在 HPV 阳性肿瘤中,HPV16 最常被检测到,但 10 种非 HPV16 型 HPV 占肿瘤的 6%至 50%,具体取决于部位。总体而言,86%的口咽癌、50%的鼻咽癌和 26%的口腔癌组织为 hrHPV 阳性。
PCR-MA 具有较低的 DNA(5ng)需求,可有效检测小组织样本;高通量;快速鉴定 HPV 类型,具有高灵敏度和特异性。PCR-MA 与 p16INK4a 联合使用可准确评估 HPV 的存在、类型和活性,被确定为 FFPE 头颈部肿瘤组织标本 HPV 检测的最佳方法。